Gdansk: Polish medical laboratory operator Diagnostyka reported on Thursday an 80.9 per cent year-on-year jump in its full-year net profit, mainly due to higher test volumes and a rise in average test prices.
The result was in line with a preliminary estimate of 223.3 million zlotys ($59.46 million).
WHY IT’S IMPORTANT
CONTEXT
Diagnostyka controlled 22 per cent of Poland’s laboratory testing market in 2023, ahead of competitors Grupa Alab with 9 per cent and Synevo, owned by Sweden’s Medicover , with 4 per cent, according to company data.
In April the medical laboratory operator acquired a 51 per cent stake in Eurodiagnostic, which manages mobile diagnostic imaging laboratories, for about 23 million zlotys.
BY THE NUMBERS
Full-year operating revenue rose 23.6 per cent year-on-year to 1.97 billion zlotys, driven by organic growth propelled by a 14.8 per cent increase in test volumes and a 7.3 per cent rise in average test prices, the company said.
On Tuesday, Diagnostyka’s management recommended a dividend of 3.13 zlotys per share for 2024.
($1 = 3.7552 zlotys)
(Reporting by Julia Kotowska and Rafal W. Nowak; Editing by Susan Fenton)
